Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer.

[1]  P. Grigsby,et al.  Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer , 2021, Clinical Cancer Research.

[2]  C. Kirisits,et al.  MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. , 2021, The Lancet. Oncology.

[3]  A. Kubiak,et al.  Pretreatment [18F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1 , 2021, Diagnostics.

[4]  J. Mountz,et al.  Diagnostic Value of FDG PET/MRI in Females With Pelvic Malignancy—A Systematic Review of the Literature , 2020, Frontiers in Oncology.

[5]  D. Georg,et al.  Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Bang-Bin Chen,et al.  PET/MRI in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival , 2020, Journal of magnetic resonance imaging : JMRI.

[7]  T. Stokke,et al.  MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer , 2020, Cancer Research.

[8]  H. Lyng,et al.  Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity , 2020, medRxiv.

[9]  E. Rofstad,et al.  DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses , 2020, Radiation oncology.

[10]  Daniela Thorwarth,et al.  Quantitative imaging for radiotherapy purposes , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  C. Fuller,et al.  Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  O. Sabri,et al.  Cervical Cancer: Associations between Metabolic Parameters and Whole Lesion Histogram Analysis Derived from Simultaneous 18F-FDG-PET/MRI , 2018, Contrast media & molecular imaging.

[13]  H. Lyng,et al.  Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients. , 2018, Cancer research.

[14]  Kathryn J Fowler,et al.  Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer , 2018, EJNMMI Research.

[15]  Christian Kirisits,et al.  Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Christian Kirisits,et al.  Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  S. Fanti,et al.  Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer , 2018, International Journal of Gynecologic Cancer.

[18]  M. Thakur,et al.  Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Christian Kirisits,et al.  The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies , 2018, Clinical and translational radiation oncology.

[20]  H. Lyng,et al.  Hypoxia in cervical cancer: from biology to imaging , 2017, Clinical and Translational Imaging.

[21]  Richard Pötter,et al.  Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET , 2017, Molecular Imaging and Biology.

[22]  N. Datta,et al.  Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis. , 2017, Gynecologic oncology.

[23]  L. Kershaw,et al.  The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability , 2017, British Journal of Cancer.

[24]  S. Purz,et al.  Parameters of simultaneous 18F-FDG-PET/MRI predict tumor stage and several histopathological features in uterine cervical cancer , 2017, Oncotarget.

[25]  H. Pu,et al.  Can Diffusion-weighted Magnetic Resonance Imaging Predict Survival in Patients with Cervical Cancer? A Meta-Analysis. , 2016, European journal of radiology.

[26]  C. Ménard,et al.  A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. Overgaard,et al.  The impact of hypoxia and its modification of the outcome of radiotherapy , 2016, Journal of radiation research.

[28]  F. Lucchesi,et al.  Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation , 2016, BMC Cancer.

[29]  Wolfgang Wadsak,et al.  Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study , 2016, PloS one.

[30]  A. Fyles,et al.  Association of Apparent Diffusion Coefficient with Disease Recurrence in Patients with Locally Advanced Cervical Cancer Treated with Radical Chemotherapy and Radiation Therapy. , 2016, Radiology.

[31]  C. Stokke,et al.  Short-course PET based simultaneous integrated boost for locally advanced cervical cancer , 2016, Radiation oncology.

[32]  O. Couturier,et al.  For avid glucose tumors, the SUV peak is the most reliable parameter for [18F]FDG-PET/CT quantification, regardless of acquisition time , 2016, EJNMMI Research.

[33]  H. Chung,et al.  Prognostic Implications of the SUVmax of Primary Tumors and Metastatic Lymph Node Measured by 18F-FDG PET in Patients With Uterine Cervical Cancer: A Meta-analysis , 2016, Clinical nuclear medicine.

[34]  P. Brandmaier,et al.  Simultaneous [18F]FDG-PET/MRI: Correlation of Apparent Diffusion Coefficient (ADC) and Standardized Uptake Value (SUV) in Primary and Recurrent Cervical Cancer , 2015, PloS one.

[35]  Thomas E Yankeelov,et al.  Correlation of tumor characteristics derived from DCE‐MRI and DW‐MRI with histology in murine models of breast cancer , 2015, NMR in biomedicine.

[36]  M. Forsting,et al.  Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  J. Robbins,et al.  PET/CT and MRI in the imaging assessment of cervical cancer , 2015, Abdominal Imaging.

[38]  Heidi Lyng,et al.  Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  Heidi Lyng,et al.  Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance. , 2012, International journal of radiation oncology, biology, physics.

[40]  Y. Liu,et al.  Diffusion-Weighted Magnetic Resonance Imaging of Uterine Cervical Cancer , 2009, Journal of computer assisted tomography.

[41]  F. Gilbert,et al.  A combined pharmacokinetic and radiologic assessment of dynamic contrast-enhanced magnetic resonance imaging predicts response to chemoradiation in locally advanced cervical cancer. , 2009, International journal of radiation oncology, biology, physics.

[42]  P. Grigsby.  The prognostic value of PET and PET/CT in cervical cancer , 2008, Cancer imaging : the official publication of the International Cancer Imaging Society.

[43]  P. Grigsby,et al.  The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival , 2007, Cancer.

[44]  Jens Overgaard,et al.  Hypoxic radiosensitization: adored and ignored. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Hedley,et al.  Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Lyng,et al.  Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[48]  P. Tofts.  Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.